Peptide · Vial
BPC 157
$8910mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
EternaGen / Research use onlyPeptide · Research use only
KPV
$45CAD
A three-amino-acid peptide fragment explored in early inflammation, immune-signalling and gut models.
Sold out
Select strength
1
Documentation review pending Fulfilled in Canada Research use only
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
KPV, clearly explained.
A three-amino-acid peptide fragment explored in early inflammation, immune-signalling and gut models.
Overview
Most KPV research comes from laboratory systems and mouse models of intestinal inflammation. Human benefit and safety have not been established, and regulators report little to no human exposure data for administered KPV products.
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Published research focuses on inflammatory signalling in cells and experimental colitis in mice.- Format
- Vial
- Available strengths
- 10mg
- Documentation
- Source review pending
Research at a glanceCell and animal evidence; administered human-drug evidence absent
Reviewed 23 July 2026View research context Specifications
Product details
- Sequence / identity
- Lys-Pro-Val
- Molecular weight
- 342.44 g/mol
- Storage and handling
- Store and handle according to the verified batch record.
Batch documentationSource review pending
Not yet publishedSupplier-origin documentation will be published only after EternaGen verifies the source and record details.
Important research-use boundary
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Intestinal inflammation models
Murine colitis studies report changes in histology, inflammatory markers and recovery under experimental conditions.
Evidence so far: Animal evidenceQuestion 02
Epithelial inflammatory signalling
Human-derived cell-line studies examine NF-κB signalling, chemokine secretion and cellular uptake.
Evidence so far: In-vitro mechanistic evidenceQuestion 03
Human administration
FDA reports no identified human exposure data for drug products containing KPV.
Evidence so far: Direct human evidence gapProposed mechanism
How researchers are investigating the mechanism.
Cell studies report effects on NF-κB-related signalling and cytokine release. Intestinal models also examine uptake through the PepT1 transporter. These findings describe experimental pathways, not established clinical outcomes.
Evidence gaps
What remains unknown?
- No adequately controlled human efficacy or safety trials were identified.
- Human pharmacokinetics, route-specific tolerability and immunogenicity remain uncharacterized.
- Cell and mouse findings cannot support a personalized treatment or dosing protocol.
Primary sources
Check the original sources.
- Primary animal studyKannengiesser et al. KPV in murine inflammatory-bowel-disease models. Inflamm Bowel Dis. 2008. PMID 18092346.
- Primary cell studyLand. KPV and inflammatory signalling in human bronchial epithelial cells. Pulm Pharmacol Ther. 2012. PMID 22837805.
- Regulatory safety reviewU.S. FDA. KPV bulk-substance safety considerations.
Related products
Continue comparing.
Peptide · Vial
GHK-CU
From CA$54.9950mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Peptide · Pen
MOTS-c
From CA$6410mg20mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.